Insulet vs Ypsomed vs DexCom and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Insulet 0.802, Ypsomed 0.12, DexCom 1.308, West Pharmaceutical Services 0.872.
* Ypsomed reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Insulet, Ypsomed, DexCom, West Pharmaceutical Services.| Metric | Insulet | Ypsomed | DexCom | West Pharmaceutical Services |
|---|---|---|---|---|
| Market Cap | $9.23B | $5.80B | $32.71B | $26.44B |
| Revenue | $802.00M | $416.00M | $1.31B | $872.00M |
| Cost of Revenue | $239.00M | $230.00M | $478.00M | $543.00M |
| Gross Profit | $563.00M | $186.00M | $830.00M | $329.00M |
| Operating Income | $130.00M | $124.00M | $318.00M | $179.00M |
| Net Income | $95.00M | $94.00M | $249.00M | $154.00M |
| R&D Expense | $88.00M | $24.00M | $153.00M | $20.00M |
| Earnings Per Share | $1.37 | $6.9 | $0.64 | $2.15 |
| Gross Margin | 70.2% | 44.6% | 63.4% | 37.7% |
| Operating Margin | 16.2% | 29.8% | 24.3% | 20.5% |
| Net Profit Margin | 11.8% | 22.5% | 19.0% | 17.6% |
| Free Cash Flow | $59.00M | $8.00M | $184.00M | $81.00M |
| Cumulative Free Cash Flow | $-38.00M | $-60.00M | $3.40B | $3.60B |
| Operating Cash Flow | $88.00M | $199.00M | $269.00M | $124.00M |
| Cash & Equivalents | $535.00M | $32.00M | $1.10B | $436.00M |
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.